International Lung Cancer Congress | Conference

TKIs Combined With Other Drugs May Prove More Effective in NSCLC

August 1st 2014

Tyrosine kinase inhibitors (TKIs) are effective as single agents in EGFR-positive non-small cell lung cancer (NSCLC), but investigators continue to ask questions about how to improve the results of these agents.

Search for Curative Therapies Continues in Lung Cancer

August 1st 2014

Curative strategies for patients with advanced lung cancer remain elusive despite several exciting advancements, according to Paul A. Bunn Jr, MD, and Primo N. Lara Jr, MD, who delivered keynote lectures during the 15th Annual International Lung Cancer Congress.

Dr. Hirsch Discusses the Role of Next-Generation EGFR Inhibitors

August 1st 2014

Fred R. Hirsch, MD, PhD Professor of Medicine and Pathology, Associate Director for International Programs, University of Colorado Cancer Center, discusses the role of next-generation EGFR inhibitors.

Experimental Drugs Hit KRAS and Downstream Targets in NSCLC

August 1st 2014

The KRAS mutation in lung cancer is an especially thorny problem, as it is an indicator of a poor prognosis and has not, in the past, been targeted specifically by any medications.

Dr. Ramalingam Discusses the Utility of Tecemotide in NSCLC

August 1st 2014

Suresh S. Ramalingam, MD, a professor of medical oncology at the Winship Cancer Institute of Emory University, discusses the utility of the vaccine tecemotide as treatment for non-small cell lung cancer.

Dr. Bunn Discusses Companion Diagnostic Tests in Lung Cancer

July 31st 2014

Paul A. Bunn, Jr., MD, professor of medicine in medical oncology, head of the division of medical oncology, University of Colorado, discusses the pros and cons of having companion diagnostic tests in lung cancer.

CT Screening for Lung Cancer an Important Life-Saving Tool

July 31st 2014

When the US Preventive Services Task Force (USPSTF) recommended last year that asymptomatic, high-risk individuals should receive annual screening for lung cancer with low-dose computed tomography (LDCT), it made a healthy decision for the American population

Dr. Mulshine Discusses New Recommendations for Lung Cancer Screening

July 31st 2014

James L. Mulshine, MD, professor, Associate Provost for Research, Vice President, Rush University Medical Center discusses new USPSTF recommendations for lung cancer screening.

Ambitious Lung-MAP Trial Launched With Five Novel Drugs

July 31st 2014

Five novel agents for the treatment of patients with advanced squamous cell carcinoma of the lung will be evaluated in the recently launched Lung-MAP trial

Lung Congress to Offer Thorough Review of Latest Research Findings

July 31st 2014

The 15th Annual International Lung Cancer Congress, which began today in Huntington Beach, California and will continue through Saturday, will offer an array of information presented by multidisciplinary experts-in a brand-new format.